First Trust Advisors’s Akebia Therapeutics AKBA Stock Holding History

First Trust Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-941,657	Closed	-$1.52M	–	2609
2025 Q4	$1.52M	Buy	+941,657	New	+$1.97M	﹤0.01%	2003

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

First Trust Advisors's AKBA Position: Q1 2026 in Review

First Trust Advisors sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 941,657 shares — an estimated $1.52M sold.

First Trust Advisors first reported a position in AKBA in Q4 2025 and held it in 1 quarter. The position peaked at $1.52M in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

First Trust Advisors reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
First Trust Advisors sold 941,657 Akebia Therapeutics shares in Q1 2026, an estimated $1.52M.
First Trust Advisors first reported a position in Akebia Therapeutics in Q4 2025 and held it in 1 quarter.
First Trust Advisors's Akebia Therapeutics position peaked at $1.52M in Q4 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.